


CLAIM AMENDMENTSIn the Claims

Claim 1. (Currently Amended) A compound having the structure



wherein n is 4;


X is N;


Z is a 5- or 6-membered nitrogen-containing monocyclic heteroaryl group which is selected from the group consisting of imidazole attached at its 4- or 5-position to the ring, aminoimidazole, alkylimidazole, alkylthioimidazole, alkylthio(amino)imidazole, amino-(alkyl)imidazole, (alkanoylamino)imidazole, aminothiazole, aminooxazole, aminooxadiazole, dialkylimidazole, alkyl(alkanoylamino)imidazole, alkyl(amino)imidazole, arylaminocarbonylamino(alkyl)imidazole, alkoxycarbonylamino(alkyl)imidazole, alkylcarbonylamino(alkyl)imidazole, aminotriazole or diaminopyrimidine;

R<sup>1</sup> is heteroaryl;

and R<sup>1</sup> may be unsubstituted or substituted with from one to five substituents;


and wherein the R<sup>1</sup> heteroaryl group is selected from






$R^2$ ,  $R^3$  and  $R^4$  are the same or different and are independently H, alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, (alkyl or aryl)<sub>3</sub>Si (where each alkyl or aryl group is independent), cycloalkyl, cycloalkenyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylalkylamino, aryl, arylalkyl, arylamino, aryloxy, cycloheteroalkyl, cycloheteroalkylalkyl, heteroaryl, heteroarylamino, heteroaryloxy, arylthio, arylsulfinyl, arylsulfonyl, thio, alkylthio, alkylsulfinyl, alkylsulfonyl, heteroarylthio, heteroarylsulfinyl, heteroarylsulfonyl, halogen, haloalkyl, polyhaloalkyl, polyhaloalkoxy, aminothio, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, hydroxy, acyl, carboxy, aminocarbonyl, alkylcarbonyl, alkoxy carbonyl, alkylcarbonyloxy, alkylcarbonylamino, arylcarbonyl, arylcarbonyloxy, arylcarbonylamino, heteroarylcarbonyl, heteroarylcarbonyloxy, heteroarylcarbonylamino, cyano, nitro, alkenylcarbonylamino, alkynylcarbonylamino, alkylaminocarbonylamino, alkenylaminocarbonylamino, alkynylaminocarbonylamino, arylaminocarbonylamino, heteroarylaminocarbonylamino, alkoxy carbonylamino, alkenyloxy carbonylamino, alkynyloxy carbonylamino, aryloxy carbonylamino, heteroaryloxy carbonylamino, aminocarbonylamino, alkylaminocarbonyloxy, alkoxy carbonylamino, 1,1-(alkoxyl or aryloxy)<sub>2</sub>alkyl

(where the two aryl or alkyl substituents can be independently defined, or linked to one another to form a ring),  $\text{S(O)}_2\text{R}^6\text{R}^7$ ,  $-\text{NR}^6(\text{C}=\text{NR}^7)\text{alkyl}$ ,  $-\text{NR}^6(\text{C}=\text{NR}^7)\text{alkenyl}$ ,  $-\text{NR}^6(\text{C}=\text{NR}^7)\text{alkynyl}$ ,  $-\text{NR}^6(\text{C}=\text{NR}^7)\text{heteroaryl}$ ,  $-\text{NR}^8(\text{C}=\text{NCN})\text{-amino}$ ,



pyridine-N-oxide,



(where Q is O or H<sub>2</sub> and n' is 0, 1, 2 or 3) or

$-\text{C}(\text{NR}^8\text{R}^9)=\text{CH}-\text{C}(=\text{O})-\text{R}^{8a}$ ; tetrazolyl, pyrazolyl, pyridyl, thiazolyl, pyrimidinyl, imidazole, oxazole, or triazole,  $-\text{PO}(\text{R}^{13})(\text{R}^{14})$ , (where  $\text{R}^{13}$  and  $\text{R}^{14}$  are independently alkyl, aryl, alkoxy, aryloxy, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroarylalkoxy, cycloheteroalkyl, cycloheteroalkylalkyl, cycloheteroalkoxy, or cycloheteroalkylalkoxy); and may be optionally independently substituted with from one to five substituents, which may be the same or different;

$\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^{8a}$  and  $\text{R}^9$  are the same or different and are independently hydrogen, alkyl, haloalkyl, aryl, heteroaryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, or cycloheteroalkyl;

or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and all stereoisomers thereof.


Claim 2. (Cancelled).


Claim 3. (Original) The compound as defined in Claim 1 wherein at least one of  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$  and  $\text{R}^4$  is aryl or heteroaryl.


Claims 4-7. (Cancelled).

Claim 8. (Previously Amended) The compound as defined in Claim 1 wherein the R<sup>1</sup> group may be substituted within from one to five of the following groups:

alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, (alkyl or aryl)<sub>3</sub>Si (where each alkyl or aryl group is independent), cycloalkyl, cycloalkenyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylalkylamino, aryl, arylalkyl, arylamino, aryloxy, cycloheteroalkyl, cycloheteroalkylalkyl, heteroaryl, heteroaryl amino, heteroaryloxy, arylthio, arylsulfinyl, arylsulfonyl, thio, alkylthio, alkylsulfinyl, alkylsulfonyl, heteroarylthio, heteroarylsulfinyl, heteroarylsulfonyl, halogen, haloalkyl, polyhaloalkyl, CF<sub>3</sub> and CF<sub>3</sub>CH<sub>2</sub>, polyhaloalkyloxy, CF<sub>3</sub>O and CF<sub>3</sub>CH<sub>2</sub>O, aminothio, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, hydroxy, acyl, carboxy, aminocarbonyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonylamino, arylcarbonyl, arylcarbonyloxy, arylcarbonylamino, heteroarylcarbonyl, heteroarylcarbonyloxy, heteroarylcarbonylamino, cyano, nitro, alkenylcarbonylamino, alkynylcarbonylamino, alkylaminocarbonylamino, alkenylaminocarbonylamino, alkynylaminocarbonylamino, arylaminocarbonylamino, heteroarylaminocarbonylamino, alkoxycarbonylamino, alkenyloxycarbonylamino, alkynyloxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, aminocarbonylamino, alkylaminocarbonyloxy, 1,1-(alkoxy or aryloxy)<sub>2</sub>alkyl (where the two aryl or alkyl substituents can be independently defined, or linked to one another to form a ring, such as 1,3-dioxane or 1,3-dioxolane), S(O)<sub>2</sub>R<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>(C=NR<sup>7</sup>)alkyl,

NR<sup>6</sup>(C=NR<sup>7</sup>)alkenyl, -NR<sup>6</sup>(C=NR<sup>7</sup>)alkynyl, ,  
NR<sup>6</sup>(C=NR<sup>7</sup>)heteroaryl, -NR<sup>8</sup>(C=NCN)-amino, pyridine-N-oxide,




(where Q is O or H<sub>2</sub> and n' is 0, 1, 2 or 3) or ; tetrazolyl, pyrazolyl, pyridyl, thiazolyl, pyrimidinyl, imidazole, oxazole or triazole; -PO(R<sup>13</sup>)(R<sup>14</sup>), (where R<sup>13</sup> and R<sup>14</sup> are independently alkyl, aryl, alkoxy, aryloxy, heteroaryl, heteroarylalkyl, heteroaryloxy,

heteroarylalkoxy, cycloheteroalkyl, cycloheteroalkylalkyl, cycloheteroalkoxy, or cycloheteroalkylalkoxy);

$R^6$ ,  $R^7$ ,  $R^8$ ,  $R^{8a}$  and  $R^9$  are independently hydrogen, alkyl, haloalkyl, aryl, heteroaryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl or cycloheteroalkyl, which substituents may be the same or different from each other and may be the same or different from the base  $R^1$  group.

Claim 9. (Original) The compound as defined in Claim 1 wherein  $R^1$  is substituted with one to five of the following substituents: alkyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, alkylcarbonylamino, heteroaryl, halo, aryl, cycloalkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, guanidiny, nitro, cycloheteroalkyl, aryloxycarbonylamino, heteroaryloxylcarbonylamino, uriedo (where the uriedo nitrogens may be substituted with alkyl, aryl or heteroaryl), heterocyclylcarbonylamino (where the heterocycle is connected to the carbonyl group via a nitrogen or carbon atom), alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino,



Where J is :  $\text{CHR}^{23}$ ,  $\text{—}\overset{\text{O}}{\underset{\text{O}}{\text{C}}}\text{—}$ ,  $\text{—}\underset{\text{R}^{24}}{\text{CH}}\text{—}\underset{\text{R}^{25}}{\text{CH}}\text{—}$  or  $\text{—}\underset{\text{R}^{24}}{\text{C}}=\underset{\text{R}^{25}}{\text{C}}\text{—}$  ;

$R^{23}$ ,  $R^{24}$  and  $R^{25}$  are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or cycloalkylalkyl;


$R^{20}$ ,  $R^{21}$ ,  $R^{22}$  are independently hydrogen, halo, alkyl, alkenyl, alkoxy, aryloxy, aryl, arylalkyl, alkylmercapto, arylmercapto, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, hydroxy or haloalkyl; and these preferred substituents may either be directly attached to  $R^1$ , or attached via an alkylene chain at an open position, which substituents may be the same or different from each other and may be the same or different from the base  $R^1$  group.

Claim 10. (Previously Presented) The compound as defined in Claim 1 wherein Z is imidazole attached at its 4- or 5-position to the ring, aminoimidazole, alkylimidazole, alkylthioimidazole, alkylthio(amino)imidazole, amino(alkyl)imidazole or (acetilamino)imidazole.




Claim 21. (Cancelled).

Claim 22. (Currently Amended) The compound as defined in Claim 14 wherein




Claim 23. (Cancelled).

Claim 24. (Currently Amended) The compound as defined in Claim 1 wherein




Claim 25. (Previously Presented) The compound as defined in Claim 1 having the structure



Claim 26. (Previously Presented) The compound as defined in Claim 1 wherein R<sup>1</sup> is phenyltetrazole, 1-(2,4-dihalo-5-alkoxyphenyltetrazol-5-yl, alkylphenyltetrazole, halophenyltetrazol, 1-(2-alkoxy-5-halophenyl)tetrazol-5-yl, 1-(3-alkyl-4-halophenyl)tetrazol-5-yl, alkoxyphenyltetrazole, alkyl(halo)phenyltetrazole, alkoxy(halo)phenyltetrazole, alkoxy(alkyl)(halo)phenyltetrazole, phenyl-alkyl-pyrazole, alkoxyphenyl-alkyl-pyrazole, halophenyl-alkyl-pyrazole, alkyl(halo)phenyl-alkyl-pyrazole, alkylphenyl-alkyl-pyrazole, alkoxy(halo)phenyl-alkyl-pyrazole, alkoxy(alkyl)phenyl-alkyl-pyrazole, dihalophenyl-alkyl-pyrazole, dialkylphenyl-alkyl-pyrazole, alkoxyphenyl-alkyl-pyrazole, halophenyl-haloalkyl-pyrazole, alkoxyphenyl(alkyl)(halo)pyrazole, phenylpyrimidine, phenyl(halo)pyrimidine, diphenylpyrimidine, halophenyl(halo)pyrimidine, dihalopyrimidine, diphenyl(halo)pyrimidine, halo(phenyl)pyrimidine, dialkyl(halo)pyrimidine, dihalophenylpyrimidine,



alkylphenylpyrimidine, alkoxyphenylpyrimidine, alkylphenyl(alkoxy)pyrimidine,  
dialkylphenyl(alkoxy)pyrimidine, alkyl(halo)phenyl(alkoxy)pyrimidine,  
alkoxy(halo)phenyl(alkoxy)pyrimidine, dihalophenyl(dialkylamino)pyrimidine,  
heteroaryl(dihalophenyl)pyrimidine, halophenylpyrimidine, alkoxy(phenyl)pyrimidine,  
haloalkoxyphenylpyrimidine, phenoxy(phenyl)pyrimidine, heteroaryl(phenyl)pyrimidine,  
dialkoxyphenylpyrimidine, dialkylphenylpyrimidine, cycloheteroalkyl(phenyl)pyrimidine,  
alkoxy(halo)phenylpyrimidine, cycloheteroalkyl(dihalophenyl)pyrimidine,  
halophenyl(alkoxy)pyrimidine, alkyl(halo)phenylpyrimidine, nitrophenylpyrimidine,  
dihalophenyl(alkoxy)pyrimidine, carboxyphenylpyrimidine, alkylcarbonylphenylpyrimidine,  
naphthylpyrimidine, alkylthiophenylpyrimidine, alkyl(halophenyl)triazole, alkyl(halo)phenyl-(alkyl)-  
triazole, alkylimidazopyridine



phenylimidazopyridine, halophenylimidazopyridine, dihalophenylimidazopyridine,  
alkoxyphenylimidazopyridine.

Claim 27. (Previously Presented) The compound as defined in Claim 1 wherein

$R^2$  is  $\text{CH}_3$  or H;

$R^3$  is  $\text{CH}_3$  or H;

$R^4$  is H;

$R^1$  is 2,3-dihydrobenzofuran-4-yl, 1-phenyltetrazol-5-yl,

1-(2,4-dichloro-5-methoxyphenyl)tetrazol-5-yl,

1-(3-chlorophenyl)tetrazol-5-yl,

1-(3-chloro-4-methyl)tetrazol-5-yl,

1-(3-methylphenyl)tetrazol-5-yl,

1-(2-chlorophenyl)tetrazol-5-yl,

1-(2-methoxy-5-chloro)tetrazol-5-yl,

1-(3-methyl-4-chlorophenyl)tetrazol-5-yl,

1-(2-methoxy-5-chlorophenyl)tetrazol-5-yl,

1-(3-methoxyphenyl)tetrazol-5-yl,

1-(2-methoxy-5-chlorophenyl)tetrazol-5-yl,

1-(3-chlorophenyl)-3-methylpyrazol-5-yl,  
1-(3-fluorophenyl)-3-methylpyrazol-5-yl,  
1-(3-methoxyphenyl)-3-methylpyrazol-5-yl,  
1-(3,5-dichlorophenyl)-3-methylpyrazol-5-yl,  
1-(3-chlorophenyl)-3-ethylpyrazol-5-yl,  
1-(3-chloro-4-methylphenyl)-3-methylpyrazol-5-yl,  
1-(2,4-dimethylphenyl)-3-methylpyrazol-5-yl,  
1-(3-chloro-4-fluorophenyl)-3-methylpyrazol-5-yl,  
1-(3-trifluoromethylphenyl)-3-methylpyrazol-5-yl,  
1-(3-chlorophenyl)-3-trifluoromethylpyrazol-5-yl,  
1-(3-methylphenyl)-3-methylpyrazol-5-yl,  
1-(3-chlorophenyl)-3-ethylpyrazol-5-yl,  
5-(3-chloro-4-fluorophenyl)pyrimidin-4-yl,  
5-(2-chlorophenyl)pyrimidin-4-yl,  
5-(3-methylphenyl)pyrimidin-4-yl,  
5-(3-trifluoromethylphenyl)pyrimidin-4-yl,  
5-(2,4-dichlorophenyl)pyrimidin-4-yl,  
5-(2,5-dimethylphenyl)pyrimidin-4-yl,  
5-(3,4-dichlorophenyl)pyrimidin-4-yl,  
5-(2,3-dimethylphenyl)pyrimidin-4-yl,  
5-(2-methoxy-5-chlorophenyl)pyrimidin-4-yl,  
5-(2-methoxy-5-fluorophenyl)pyrimidin-4-yl,  
5-(3-methyl-4-fluorophenyl)pyrimidin-4-yl,  
5-(3-chloro-4-fluorophenyl)-2-methoxy-pyrimidin-4-yl,  
5-(3-chloro-4-fluorophenyl)-2-dimethylamino-pyrimidin-4-yl,  
5-(3-chloro-4-fluorophenyl)-2-morpholinyl-pyrimidin-4-yl,  
1-(3-chlorophenyl)-3-methyltriazol-5-yl,  
1-(3-chloro-4-methylphenyl)-3-methyltriazol-5-yl,  
5-(2,5-dichlorophenyl)pyrimidin-4-yl,  
5-(3-chlorophenyl)pyrimidin-4-yl,  
5-(3-trifluoromethoxyphenyl)pyrimidin-4-yl,  
5-(2-chlorophenyl)-2-methoxypyrimidin-4-yl,  
5-(3-chlorophenyl)-2-methoxypyrimidin-4-yl,  
5-(3-trifluoromethylphenyl)-2-methoxypyrimidin-4-yl,

5-(2,4-dichlorophenyl)-2-methoxypyrimidin-4-yl,


5-(3-methylphenyl)-2-methoxypyrimidin-4-yl,
















5-(2,5-dimethylphenyl)-2-methoxypyrimidin-4-yl, or


5-(3-methyl-4-fluorophenyl)-2-methoxypyrimidin-4-yl;


Z is 2-amino-5-methyl-imidazol-4-yl, 2,5-dimethylimidazol-4-yl, 2-amino-5-ethyl-imidazol-4-yl, 2-amino-5-isopropyl-imidazol-4-yl, 2-aminocarbonylamino-5-methyl-imidazol-4-yl, 5-methyl-imidazol-4-yl, imidazol-4-yl, or 4-methylimidazol-5-yl.







Claim 28. (Previously Presented) A compound having the structure





















































































































Claim 29. (Previously Presented) A compound having the structure













Claim 30. (Previously Presented) A compound having the structure




Claim 31. (Original) A pharmaceutical composition comprising a compound as defined in Claim 1 and a pharmaceutically acceptable carrier therefor.

Claims 32-62. (Cancelled).

Claim 63. (Previously Presented) A compound having the following structure





Claim 64. (Previously Presented) A compound having the structure



wherein n is 4;

X is N;


Z is a 5- or 6-membered nitrogen-containing monocycle heteroaryl group which is selected from the group consisting of imidazole attached at its 4- or 5-position to the ring, aminoimidazole, alkylimidazole, alkylthioimidazole, alkylthio(amino)imidazole, amino(alkyl)imidazole, (alkanoylamino)imidazole, aminothiazole, aminooxazole, aminooxadiazole, dialkylimidazole, alkyl(alkanoylamino)imidazole, alkyl(amino)imidazole, arylaminocarbonylamino(alkyl)imidazole, alkoxycarbonylamino(alkyl)imidazole, alkylcarbonylamino(alkyl)imidazole, aminotriazole or diaminopyrimidine;

R<sup>1</sup> is tetrazolyl, pyrazolyl, thiazolyl, , oxazole, triazole or  ;


and R<sup>1</sup> may be unsubstituted or substituted with from one to five substituents;

R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are the same or different and are independently H, alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, (alkyl or aryl)<sub>3</sub>Si (where each alkyl or aryl group is independent), cycloalkyl, cycloalkenyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino,

arylalkylamino, aryl, arylalkyl, arylamino, aryloxy, cycloheteroalkyl, cycloheteroalkylalkyl, heteroaryl, heteroarylamino, heteroaryloxy, arylthio, arylsulfinyl, arylsulfonyl, thio, alkylthio, alkylsulfinyl, alkylsulfonyl, heteroarylthio, heteroarylsulfinyl, heteroarylsulfonyl, halogen, haloalkyl, polyhaloalkyl, polyhaloalkoxy, aminothio, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, hydroxy, acyl, carboxy, aminocarbonyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonylamino, arylcarbonyl, arylcarbonyloxy, arylcarbonylamino, heteroarylcarbonyl, heteroarylcarbonyloxy, heteroarylcarbonylamino, cyano, nitro, alkenylcarbonylamino, alkynylcarbonylamino, alkylaminocarbonylamino, alkenylaminocarbonylamino, alkynylaminocarbonylamino, arylaminocarbonylamino, heteroarylaminocarbonylamino, alkoxycarbonylamino, alkenyloxycarbonylamino, alkynyloxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, aminocarbonylamino, alkylaminocarbonyloxy, alkoxycarbonylamino, I,I-(alkoxy or aryloxy)<sub>2</sub>alkyl (where the two aryl or alkyl substituents can be independently defined, or linked to one another to form a ring), S(O)<sub>2</sub>R<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>(C=NR<sup>7</sup>)alkyl, -NR<sup>6</sup>(C=NR<sup>7</sup>)alkenyl, -NR<sup>6</sup>(C=NR<sup>7</sup>)alkynyl, -NR<sup>6</sup>(C=NR<sup>7</sup>)heteroaryl, -NR<sup>8</sup>(C=NCN)-amino,



pyridine-N-oxide,



(where Q is O or H<sub>2</sub> and n' is 0, 1, 2 or 3) or

$\text{---C}(\text{NR}^8\text{R}^9)=\text{CH---C}(=\text{O})\text{---R}^{8a}$ ; tetrazolyl, pyrazolyl, pyridyl, thiazolyl, pyrimidinyl, imidazole, oxazole, or triazole, -PO(R<sup>13</sup>)(R<sup>14</sup>), (where R<sup>13</sup> and R<sup>14</sup> are independently alkyl, aryl, alkoxy, aryloxy, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroarylalkoxy, cycloheteroalkyl, cycloheteroalkylalkyl,

cycloheteroalkoxy, or cycloheteroalkylalkoxy); and may be optionally independently substituted with from one to five substituents, which may be the same or different;

$R^6$ ,  $R^7$ ,  $R^8$ ,  $R^{8a}$  and  $R^9$  are the same or different and are independently hydrogen, alkyl, haloalkyl, aryl, heteroaryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, or cycloheteroalkyl;


or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and all stereoisomers thereof.

Claim 65. (Previously Presented) The compound as defined in Claim 64 wherein Z is imidazole attached to its 4- or 5-position to the ring, aminoimidazole, alkylimidazole, alkylthioimidazole, alkylthio(amino)imidazole, amino-(alkyl)imidazole, (alkanoylamino)imidazole, aminothiazole, aminooxazole, aminooxadiazole, dialkylimidazole, alkyl(alkanoylamino)imidazole, alkyl(amino)imidazole, arylaminocarbonylamino(alkyl)imidazole, alkoxycarbonylamino(alkyl)imidazole, alkylcarbonylamino(alkyl)imidazole, aminotriazole or diaminopyrimidine.

Claim 66. (Previously Presented) The compound as defined in Claim 1 wherein the  $R^1$  group may be substituted within from one to five of the following groups:


alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, (alkyl or aryl)<sub>3</sub>Si (where each alkyl or aryl group is independent), cycloalkyl, cycloalkenyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylalkylamino, aryl, arylalkyl, arylamino, aryloxy, cycloheteroalkyl, cycloheteroalkylalkyl, heteroaryl, heteroaryl amino, heteroaryloxy, arylthio, arylsulfinyl, arylsulfonyl, thio, alkylthio, alkylsulfinyl, alkylsulfonyl, heteroarylthio, heteroarylsulfinyl, heteroarylsulfonyl, halogen, haloalkyl, polyhaloalkyl such as  $CF_3$  and  $CF_3CH_2$ , polyhaloalkyloxy such as  $CF_3O$  and  $CF_3CH_2O$ , aminothio, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, hydroxy, acyl, carboxy, aminocarbonyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonylamino, arylcarbonyl, arylcarbonyloxy, arylcarbonylamino, heteroarylcarbonyl, heteroarylcarbonyloxy, heteroarylcarbonylamino, cyano, nitro, alkenylcarbonylamino, alkynylcarbonylamino, alkylaminocarbonylamino, alkenylaminocarbonylamino, alkynylaminocarbonylamino, arylaminocarbonylamino, heteroarylaminocarbonylamino, alkoxycarbonylamino, alkenyloxycarbonylamino, alkynyloxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, aminocarbonylamino, alkylaminocarbonyloxy, 1,1-(alkoxy or aryloxy)<sub>2</sub>alkyl (where the two aryl or

alkyl substituents can be independently defined, or linked to one another to form a ring, such as 1,3-dioxane or 1,3-dioxolane),  $S(O)_2R^6R^7$ ,  $-NR^6(C=NR^7)alkyl$ ,



$NR^6(C=NR^7)alkenyl$ ,  $-NR^6(C=NR^7)alkynyl$ ,

$NR^6(C=NR^7)heteroaryl$ ,  $-NR^6(C=NCN)-amino$ , pyridine-N-oxide,




(where Q is O or H<sub>2</sub> and n' is 0, 1, 2 or 3) or  $\begin{matrix} NR^8R \\ | \\ C=CH-C \\ || \\ O \end{matrix} -R^{8a}$ ; tetrazolyl, pyrazolyl, pyridyl, thiazolyl, pyrimidinyl, oxazole or triazole;  $-PO(R^{13})(R^{14})$ , (where R<sup>13</sup> and R<sup>14</sup> are independently alkyl, aryl, alkoxy, aryloxy, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroarylalkoxy, cycloheteroalkyl, cycloheteroalkylalkyl, cycloheteroalkoxy, or cycloheteroalkylalkoxy);

R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>8a</sup> and R<sup>9</sup> are independently hydrogen, alkyl, haloalkyl, aryl, heteroaryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl or cycloheteroalkyl, which substituents may be the same or different from each other and may be the same or different from the base R<sup>1</sup> group.

Claim 67. (Previously Presented) The compound as defined in Claim 64 wherein R<sup>1</sup> is substituted with one to five of the following substituents: alkyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, alkylcarbonylamino, heteroaryl, halo, aryl, cycloalkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, guanidinyl, nitro, cycloheteroalkyl, aryloxycarbonylamino, heteroaryloxylcarbonylamino, uriedo (where the uriedo nitrogens may be substituted with alkyl, aryl or heteroaryl), heterocyclylcarbonylamino (where the heterocycle is connected to the carbonyl group via a nitrogen or carbon atom), alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino,






Where J is:  $\text{CHR}^{23}$ ,  $\text{—}\overset{\text{O}}{\underset{\text{O}}{\text{C}}}\text{—}$ ,  $\text{—}\underset{\text{R}^{24}}{\text{CH}}\text{—}\underset{\text{R}^{25}}{\text{CH}}\text{—}$  or  $\text{—}\underset{\text{R}^{24}}{\text{C}}=\underset{\text{R}^{25}}{\text{C}}\text{—}$ ;

$\text{R}^{23}$ ,  $\text{R}^{24}$  and  $\text{R}^{25}$  are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or cycloalkylalkyl;

$\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  are independently hydrogen, halo, alkyl, alkenyl, alkoxy, aryloxy, aryl, arylalkyl, alkylmercapto, arylmercapto, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, hydroxy or haloalkyl; and these substituents may either be directly attached to  $\text{R}^1$ , or attached via an alkylene chain at an open position, which substituents may be the same or different from each other, and may be the same or different from the base  $\text{R}^1$  group.


Claim 68. (Previously Presented) The compound as defined in Claim 64 wherein Z is imidazole attached at its 4- or 5-position to the ring, aminoimidazole, alkylimidazole, alkylthioimidazole, alkylthio(amino)imidazole, amino(alkyl)imidazole or (acetylamino)imidazole.

Claim 69. (Currently Amended) The compound as defined in Claim 64 wherein the moiety




Claim 70. (Previously Presented) The compound as defined in Claim 64 wherein  $\text{R}^2$  and  $\text{R}^3$  are independently H, lower alkoxy or aryl, and  $\text{R}^4$  and  $\text{R}^5$  are each hydrogen.

Claim 71. (Previously Presented) The compound as defined in Claim 64 wherein R<sup>1</sup> is













Claim 72. (Previously Presented) The compound as defined in Claim 64 wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and/or R<sup>4</sup> may be joined together with the N atom and/or carbons to which they are attached to form a non-aromatic ring.

Claim 73. (Currently Amended) The compound as defined in Claim 64 wherein



Claim 74. (Previously Presented) The compound as defined in Claim 64 having the structure





Claims 75 and 76. (Cancelled).